Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting

600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219
Thursday, October 20, 2011 - 10:00 a.m.

Welcome and Comments from DMAS' Director	**Cynthia B. Jones**
Comments from the Secretary of Health and Human Resources	**The Honorable William Hazel, M.D.**
Call to Order	**Randy Axelrod, M.D., Chairman**
Drug Utilization Review (DUR) Board Update	**Avtar Dhillon, MD, DMAS DUR Board**
Provider Synergies Services Update	**Debbie Moody, Clinical Manager**
Approval of Minutes From April 22, 2011 Meeting	**P&T Committee Members**
PDL Management	**P&T Committee Members**

- **Old Business**
  - Butrans – Polypharmacy
  - Cough and Cold – Quantity Limits for Pseudoephedrine Products
  - Effient® – utilization by physician specialty
  - Pradaxa® - utilization
  - Review of Smoking Cession Programs
  - Rosiglitazone - REMS update
- **PDL Phase II – New Drug Review (Therapeutic Class)**
  - Axiron® (Androgenic Agents, Topical)
  - Brilinta™ (Platelet Aggregation Inhibitors)
  - Bromfenac ophthalmic solution (Ophthalmics, Anti-Inflammatory)
  - Cyclobenzaprine ER (Skeletal Muscle Relaxants)
  - Epinastine (Ophthalmics for Allergic Conjunctivitis)
  - Levofloxacin (systemic Quinolones)
  - Methylphenidate ER (Stimulants and Related)
  - Orencia® 125 Mg/ml Syringe (Cytokine And Cam Antagonists, Self-Injectable)
  - Sprix® (NSAIDs)
  - Syeda™, Zeosa™ , Ethinyl Estradiol 0.03mg, & Levonorgestrel 0.15mg (Contraceptives, Oral)
  - Tradjenta™ (Hypoglycemics, Incretin Mimetics/Enhancers)
  - Xarelto ™ (Anticoagulants)
- **PDL Phase I – Annual Review**
  - ***Antivirals***
    - Hepatitis C
  - ***Cardiac Medications***
    - Angiotensin Modulators
      - Angiotensin-Converting Enzyme and Direct Renin Inhibitors
      - Angiotensin II Receptor Antagonists (includes combination products)
      - Angiotensin Modulators Combinations
    - Beta Blockers
    - Calcium Channel Blockers (includes dihydropyridine & non-dihydropyridine agents)
    - Lipotropics

- Statins (includes combinations with niacin, CAI agent, CCBs)
- Other (includes Fibric Acid derivatives, Omega 3 fatty acid, Niacin, Bile Acid Sequestrants and CAI agent)

- Pulmonary Arterial Hypertension (PAH) Agents
  - PDE-5 Inhibitors
  - Potential new products to be reviewed for possible inclusion
    - Endothelin-1 agents including Letairis® and Tracleer®
    - Prostacyclin analogues including Tyvaso™ and Ventavis®

- ***Central Nervous System***
  - Sedative Hypnotics and Other Hypnotics
- ***Endocrine & Metabolic Agents***
  - Growth Hormones
  - Erythropoiesis Stimulating Proteins
  - Progestins for Cachexia
- ***Gastrointestinal***
  - Histamine-2 Receptor Antagonists
  - Proton Pump Inhibitors
  - Ulcerative Colitis (oral and rectal)
- ***Genitourinary***
  - Bladder Relaxants
  - BPH Agents
    - Alpha Blockers for BPH
    - Androgen Hormone Inhibitors
  - Phosphate Binders
- ***Immunologic Agents***
  - Topical Immunomodulators
- ***Respiratory***
  - Antihistamines – 2nd generation (includes combination products)
  - Bronchodilators, Beta Adrenergic
    - Short Acting
    - Long Acting
  - Bronchodilators, Anticholinergic
  - Intranasal Rhinitis Agents
    - Intranasal Steroids
    - Intranasal Antihistamines
    - Intranasal Anticholingerics
  - Inhaled Corticosteroids
  - Self-Injectable Epinephrine

Confidential Meeting ♦ **Pricing Information Discussion**	**P&T Committee Members, DMAS & PS Staff Pursuant to 42 U.S.C. §1396r-8**
PDL Recommendations and Vote	**P&T Committee Members**
Criteria Discussion of Phase II New Drugs**	**P&T Committee Members**
Criteria Discussion of PDL Phase I Drug Classes**	**P&T Committee Members**
Next Meeting – April 19, 2012	**Randy Axelrod, M.D., Chairman**

***Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes in Phase I which are scheduled for review at the October meeting, potential new drug classes, and specific new drugs in PDL Phase I and II classes listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- Current Drugs on the PDL phase I Drug Classes – October 2010 to present
- New Drugs in PDL Phase I or II Drug Classes – October 2009 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov **by close of business on September 23rd 2011.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov **by close of business on September 23rd 2011**.